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ABSTRACT
Biosimilars are biological products that are the replica of their innovator biopharmaceuticals. These are developed after patent expiration of 
innovator biopharmaceuticals and are submitted for separate marketing approval. In view of the structural and manufacturing complexities of 
biopharmaceuticals, biosimilars should not be considered as “biological generics.” The objective of the article will address the current Indian scenario 
conducting the clinical trial biological and biosimilar product regulatory requirements for approval of biological and biosimilar product. The New 
India Guidelines “Draft Guidelines on Similar Biologics were announced in June 2012, by the department of biotechnology at Boston bio and available 
in India.
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INTRODUCTION
A biosimilar is a biologic product that is similar, but not identical, 
to a reference product, and therefore, requires separate marketing 
approval on patent expiration of the reference product. Biosimilars are 
not generic versions of biologics [1]. The active ingredient in a generic 
small molecule drug is a single molecular structure and can readily 
be reproduced by chemical synthesis, but the active substance in a 
biologic product is a collection of large protein isoforms, thus making 
reproduction more complex [1,2]. “Biosimilar” is the term used in 
Europe and the U.S., “follow-on pharmaceuticals” in Japan, “subsequent 
entry biologics” in Canada, and “biocomparables” in Mexico. The original 
version of a biologic is referred to as the “originator,” “innovator,” 
“pioneer,” or “reference” drug. A biologic drug, in general, is also referred 
to as a “biopharmaceutical,” “bio drug,” “biologic,” or “biological.”
ORIGIN AND MANUFACTURING
Biologics, whether reference or biosimilar, are produced with living 
cells through the use of biotechnology such as recombinant DNA 
technology, controlled gene expression, or antibody technologies [2,3]. 
Since biologics are made with cells in culture or whole organisms such 
as plants, animals, and microorganisms, they are inherently more 
variable than a small-molecule drug, such as aspirin, which is made by 
chemical synthesis [2,4]. Recombinant DNA technology refers to the 
process of using enzymes to cut and paste together DNA sequences of 
interest. The recombined DNA sequences can be placed into vectors 
that carry the DNA into a host cell, where the customized recombined 
DNA sequence can be copied or translate [5]. First-generation biologics 
were made directly from human and animal by-products such as human 
blood and porcine insulin. Second-generation biologics, however, are 
made by genetically engineering DNA within living organisms [6]. The 
benefit of this is notable in the example of immunological compatibility 
of genetically-engineered insulin versus porcine insulin, which can 
cause long-term immunological complications in some patients [4]. 
The use of recombinant DNA technology to produce insulin depicts the 
manufacturing process for biologics.
Methods for manufacturing biologics are more complex than for small 
molecule drugs and involve several steps that are subject to variations 
affecting the biological and clinical properties of the product [6,7]. The 
sensitivity of biologics to manufacturing conditions is much greater 
than for chemical small molecules [8]. It is natural for proteins, once 
isolated from the host cells that produced them, to undergo certain 
chemical changes such as oxidation and deamidation. Subtle time-
dependent changes in the shape of a protein can trigger undesirable 
effects such as protein insolubility, loss of biological function, or 
increased immunogenicity because of exposure of antigenic segments 
of the molecule that would usually be hidden from the immune system 
(Fig. 1).
The organisms from which the biosimilar and reference drug are 
produced may not be identical, and the production process of the 
reference drug remains confidential, even after the patent for the 
process expires [9]. As a result, the biosimilar and the reference 
biologic are not exact duplicates. Inherent variability also exists for the 
reference biologic and it must be noted that no batch of any reference 
product is identical to the previous one, as depicted by the difference 
between the middle molecule and one to its right. Note the different 
orientations of yellow lines each molecule, which represent minor 
alterations in post-translational modifications that should not affect 
clinical efficacy [10].
HISTORY
“Virus, therapeutic serum, toxin, vaccine, blood, blood component or 
derivative, allergenic product, or analogous products, applicable to the 
prevention treatment, or cure of disease or condition of human beings” 
are generally considered as biological products. They have been around 
for nearly two centuries, since the development of first commercial 
Blutserum therapy (serum therapy) by Behring and Kitasato. Behring’s 
diphtheria serum therapy was first clinically tested in 1891 and by 
1894, Faberwerke Hoechst launched the first biological product, 
antidiptheria serum (e.g., crude polyclonal antibody preparation), to 
combat a serious diphtheria epidemic in Europe).
One of the next advances in biological products was the introduction 
of heterologous insulin purified from pigs and cows, marketed as 
Iletin by Eli Lilly starting in 1923 as life-saving treatment for patients 
with type 1 diabetes mellitus. While additional animal serum-derived 
products were developed over the next half century, they increased the 
use of biologics therapy in incremental stages. The scenario changes 
last quarter of the 20th century, with the advent of recombinant protein 
technology. Genentech led the path to production of recombinant 
therapeutic proteins in the late 1970s by cloning and expressing human 
somatostatin, insulin growth hormone, and human growth hormone 
(HGH) in Escherichia coli [11].
Recombinant human insulin, HumulinR, the first recombinant human 
therapeutic protein was developed by Genentech and Eli Lilly, and the 
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first approved for sale in the US on October 30, 1982 [11]. The fully 
human protein, HumulinR, helped to eliminate the issues with immune 
responses directed against heterologous insulin from livestock. 
In the 27 years since Humulin was brought into the market, more 
than 165 biological products have been marketed for a broad array 
of therapeutic diseases. While few of these, such as a – antitrypsin 
and alpha-1-protenaise, are still purifies from human blood, the vast 
majority of biologics on the market today are from recombinant 
sources, requiring reliable, and consistent cell-based production 
platforms.
CLASSIFICATION OF BIOLOGICAL PRODUCT
Leader et al. have categorized a protein therapeutics which constitutes 
most of the biological products into four functional groups:
•	 Protein	 therapeutics	with	 enzymatic	 or	 regulatory	 activity	
(e.g., insulin growth hormone, factor 1x replacement therapies, 
and beta-gluco-cerebrosidase replacement therapy for Gaucher’s 
diseases.
•	 Protein	therapeutics	with	special	targeting	activity	(e.g.,	monoclonal	
antibodies	 that	 bind	 specific	 therapeutic	 targets,	 such	 as	 the	
antitumor	necrosis	factor-α	biologics.
•	 Vaccines	(e.g.,	human	papillomavirus	(HPV)	vaccine	made	using	HPV	
major virus-like particles containing HPV major capsid protein L 1); 
and,
•	 Diagnostics	(e.g.,	biomarkers	such	as	glucagon,	and	imaging	agents	
such as technetium-labeled antibodies).
CURRENT SCENARIO
Contents
Biological products approved in India
History of biological products in India: Recombinant hepatitis-B-surface 
antigen was the first indigenously developed and commercialized 
biopharmaceuticals in the year 1997. Several biopharmaceuticals 
have been indigenously developed and have received approval the last 
13 years.
Regulatory approval process for biological products
Biological products are considered as NEW DRUGS as per the Indian 
“Drugs and Cosmetics Act.” Products intended to be marketed in India 
are regulated by either drug Controller General of India or by DCGI or by 
DCGI and Department of Biotechnology (DBT). The history regulatory 
related to drug import, manufacture and sale are covered under the 
Drugs and Cosmetics Act of 1940 and Drugs and Cosmetics Rules of 
1945. The Act’s main objective is to ensure that available human drugs 
are safe efficacious and conform to prescribed quality standards, and 
marketed cosmetics are safe for use. CDSCO office along with the Indian 
Council of Medical Research have adopted international regulatory 
guidelines for biomedical research on human subjects in 2000 and 
Indian GCP guidelines were released by CDSCO office and Guidance 
on Common Technical document for the NDA application were other 
initiatives for streamlining the requirements for conducting clinical 
trial and new drug approval process in India.
Currently, clinical trials in India are regulated by Schedule Y of the 
Drug and Cosmetics Rules, 1945. During the amendment of drugs and 
cosmetics rules, 2005, the Schedule Y was extensively revised to bring 
the Indian regulations on par with internationally accepted definitions 
and procedures. Schedule Y defines the requirement and guidelines for 
and/or manufacture of new drugs for sale of clinical trials.
Clinical trial requirements for biosimilars or follow-on biologics
The demonstration of bioequivalence of the generic non-biologic 
medicine with reference products usually appropriate and sufficient 
to infer therapeutic equivalence between the generic non-biologic 
medicine and the reference product. However, the approach 
established for generic non-biologic medicines is not suitable for 
development, evaluation and licensing of biosimilars (terminology 
used in Europe) or “follow-on biologics” (terminology used in the 
USA). To understand the clinical trial requirements, a brief outline 
of the dossier requirement for the approval for biosimilar with the 
reference from WHO guidelines is mentioned here. The office of DCGI 
has circulated draft biosimilar guidelines for India for comments from 
the stakeholders. The amount of data required evaluates the safety 
and efficacy of biosimilars is highly variable and is driven largely 
by the molecule evaluated and decided by the National Regulatory 
Authority, DCGI in India. Comparability to the innovator product is 
one of the most important requirements for a biosimilar product and 
includes an evaluation of physiochemical properties, biological pre-
clinical and clinical comparability. The requirement for comparability 
data from a quality standpoint is significantly higher for biosimilar 
development compared to the development of a new and independent 
biological product. However, this extensive quality evaluation from a 
physiochemical, pharmaceutical, and biologic perspective reduces the 
amount of non-clinical and clinical data required for an approval of a 
biosimilar product. The requirement for biosimilar is organized and 
explained as shown in Table 1.
Manufacturing and quality
The administrative information summary should include details on the 
biosimilar product, its substance, raw materials, and manufacturing 
process. Differences with relevant attributes of the reference medicinal 
product should also be included. Any other changes introduced 
during the development which could affect the comparability should 
be highlighted. A full quality dossier is required for biosimilars. This 
should be supplemented by the demonstration of comparability (the 
exercise that will provide the two products have a similar profile in 
terms of quality safety efficacy).
Non-clinical studies
Before initiating non-clinical studies, results from the quality 
comparability studies including physiochemical and biological 
characterization studies should be reviewed from the point of view of 
the potential impact on efficacy and safety.
Clinical studies
The clinical comparability exercises is a stepwise approach that should 
ideally start with the pharmacokinetics and pharmacodynamics studies 
Fig. 1: Comparison between reference and biologic. (a) Biosimilar. (b and c) Biologic
a b c
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followed by the efficacy and clinical safety and clinical efficacy trials 
will be required, the clinical studies and nature of a biosimilar trial are 
likely to depend on the product class. All the clinical studies should 
address the immunogenicity characteristics.
REQUIREMENTS FOR CONDUCTING CLINICAL TRIAL IN INDIA
For new drugs discovered in India, Phase 1 clinical trials may 
be conducted in India or outside India and submitted as per the 
requirements. However, for new drugs discovered in countries other 
than India, first in human studies cannot be conducted in India but 
in some cases repeat dose studies can be conducted subjected to 
regulatory approvals. The Phase 1 data need to be submitted along 
with the application for conduct of Phase 2 trials, and subsequently, 
for Phase 3 trials. Phase 3 trials are required to be conducted in India 
before permission to market the drug in India is granted. Application for 
permission to initiate specific phase of clinical trial should be submitted 
in Form 44 and Appendix 1. A clinical trail application utilizes Form 44, 
accompanied by documents pertaining to chemical and pharmaceutical 
information, animal pharmacology, toxicology data, and clinical 
pharmacology data. Other trial-related documents that must be 
submitted for approval includes the Investigator’s Brochure, trail 
protocol, case report form, informed consent document, investigator’s 
undertaking. In addition, the trial’s regulatory status of the trial in other 
countries must be reported. The requirements in respect of chemistry 
and Pharmaceuticals information have been elaborated separately for 
biological products while other requirements for conduct of clinical 
trial and other requirements remain the same as per Schedule Y of 
Drugs and Cosmetics Rules 1945. A checklist has been published by the 
CDSCO office for the conductance of Phase 1, 2, and 3 clinical trials as 
given. The anticipated timeline for the approval of conduct of the study 
is around 8-12 if direct approval is granted. But if it is a new drug/First 
in human trials, the applications are referred to the IND Committee 
which would take anywhere from 12 to 24 weeks to give their opinion, 
based on this opinion the DCGI office may approve (with or without 
some changes to the protocol) or seek clarifications or decline approval.
Import license/Test license in Form 11 is obtained from DCGI whenever, 
the clinical study drugs, biological samples, diagnostics kits are to be 
imported for the purpose of tests and analysis during the conduct of 
clinical trials/BA-BE studies. The documents to be submitted for the 
import License include:
Application with form 12
•	 The	purpose	of	import	and	detailed	utilization	indicating	nature	of	
tests and quantity required for each test.
•	 Authorization	letter	from	the	sponsor	for	the	import	license
•	 Justification	and	utilization	breakup
The anticipated timeline for the DCGI approval would be 4-6 weeks. 
Once the license is issued, it is valid for multiple shipments for 1 year or 
the till the quantities approved are exhausted whichever is earlier. After 
the expiry of import kicense, new application needs to be submitted for 
DCGI approval. When the biological samples (e.g., blood, serum, plasma, 
and urine) are required to be collected during the clinical trial and 
exported out of the country for analysis, a “No Objection Certificate” 
(NOC) has to be obtained from DCGI. The application is applied toails, 
the DCGI with the following information like type of sample, shipment 
details, address of the laboratory where the analysis to be conducted 
and purpose of the export of biological sample. The export NOC could 
also be used applied parallel with the clinical study approval (Fig. 2).
INDIAN GUIDELINES
The New India Guidelines “Draft Guidelines on Similar Biologics: 
Regulatory Requirements for Marketing Authorization in India,” were 
announced in June 2012, by DBT. The Indian Guidelines on similar 
biologics address the premarketing and post marketing regulatory 
requirement (i.e., “comparability exercises”), and also address the 
requirements related to manufacturing process and quality control. 
As such these Indian guidelines on similar biologics are comparable 
in many respects to biosimilar guidelines of USA and EU. India has 
adopted a “sequential approach” (like “stepwise approach” US and 
EU) to market biosimilar products [12]. The Review Committee on 
genetic manipulation of the Genetic Engineering Approval Committee 
with the permission of DCGI, approves clinical trials to be conducted 
in India related to biosimilar therapeutic products. The biosimilar has 
to demonstrate comparableof clinical studies, viz., Pharmacokinetics 
and toxicology. (Safety pharmacology, reproduction toxicology, 
mutagenicity, and carcinogenicity) and clinical studies (efficacy and 
tolerability for each indication) before it gets approval for all indication 
of the reference medicine [13].
Biosimilars in India [14] consist primarily of vaccine, monoclonal 
antibodies, recombinant proteins and diagnostics, insulin (wosulin, 
insugen, recosulin), erythropoietin (hemax, epofer, wepox, ceriton, 
epofit), hepatitis B vaccine (Shanvac B, Revac B, Enivac B, Biovac B, 
Genevac B, Bevac), granulocyte colony stimulating factor (GCSF–
Grastim, Neukine), streptokinase (indikinase, shankinase, STPase), 
interferon alpha 2B (shanferon), Rituxinab (MAb), epidermal growth 
factor receptor (anti-EGFR) MAb–(reditux, bioMABEGFR). Status of 
similar biologics in India is elaborated in Table 2 [15-17].
There are about 100 biopharmaceutical companies actively involved in 
research and development, manufacturing and marketing of biosimilar 
therapeutic products in India. There were 14 therapeutic drugs (similar 
biologics)	available	 in	50	brands	 in	2005;	The	number	has	 increased	
to 20 therapeutic drugs in 250 brands in 2011. Biosimilar therapeutic 
products include insulin, erythropoietin, chorionic gonadotropin, 
streptokinase, interferon, and heparin. The growing biosimilars 
market offers huge potential for companies involved in manufacturing, 
research, and development [18].
Fig. 2: Manufacture of biopharmaceutical and source variation 
between manufacturer of innovator biopharmaceutical and 
biosimilar
Table 1: Format of dossier-module of common technical document
1 Administrative information Normal requirements
2 Quality (chemical, pharmaceutical and biological information Full+comparability exercise
3 Non-clinical study reports Reduced++comparability exercise
4 Clinical study reports Reduced++comparability exercise
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After completion of the clinical study detailed reports should be 
submitted to DCGI. The dossier should be in CTD format that must be 
approved by DCGI. The DCGI recommends license for manufacturing 
after inspection of the facility. After approval of biosimilar for the 
market, post-marketing surveillance is essential for at least 4 months 
and pharmacovigilance monitoring throughout the study. In addition to 
that periodic safety update report should be reported to DCGI in every 
6 months for first 2 years. Any change in process must to be authorized 
by DCGI [19].
CONCLUSION
Biosimilars are copy drugs similar to biological drugs that have already 
been authorized (the biological reference medicine), hence similar 
but not identical. Indian guidelines define a “similar biologics” as a 
biological product/drug produced by genetic engineering techniques 
and claimed to be “similar” in terms of safety, efficacy, and quality to 
a reference biologics, which has been authorized by DCGI for safe use 
in India. The active substance of biosimilar medicine is similar to one 
of the biological reference medicine and used in general at the same 
dosage to treat the same disease. Biosimilars are entity based (including 
product process), regulatory-based (under an abbreviated testing), and 
market-based (same manufacturers, different trade names).
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